Komori
Share Issuance and Disposal4594BrightPath Biotherapeutics Co.,Ltd.Pharmaceuticals

Notice Regarding Completion of Payment for the Issue Price of the 21st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment

Payment of the total issue price for the 21st Series Stock Acquisition Rights resolved on 18 September 2026 has been completed by the allottee. A total of 345,000 stock acquisition rights were allotted to PhillipCapital Securities Co., Ltd., and the issuance of up to 34,500,000 new shares is expected upon their future exercise.

Worth reading
72In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2415000
¥ (total issue price)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Completion of Payment of the Issue Price for the 21st Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through a Third-Party Allotment

Who receives how much

34,500,000 shares (345,000 stock acquisition rights, 100 shares per right)

PhillipCapital Securities Co., Ltd.: 345,000 stock acquisition rights (34,500,000 shares)

The lower thin line represents the existing number of shares to which these shares will be added.

¥7 per stock acquisition right
Total issue value

¥2,415,000

Amount of funds to be raised
¥1,952,915,000 (including the value of assets contributed upon exercise of these stock acquisition rights and related amounts, net of issuance expenses)
Terms of the stock acquisition rights
Exercise price
Initially ¥57. Subject to an adjustment clause. The adjusted exercise price will be 97% of the closing price on the price calculation date, rounded up to the nearest yen, with a floor of ¥29. If exercised in excess of the limit, the exercise price will be adjusted with the closing price on the resolution date as the floor.
Exercise period
From 6 October 2026 to 6 October 2027
Number of Stock Acquisition Rights
Total issued: 345,000 stock acquisition rights; unexercised balance: Not disclosed
Intended allottee's holding policy
A repurchase agreement was executed requiring approval by the Company's Board of Directors if the allottee transfers these stock acquisition rights.
Payment date
5 October 2026
Most recent equity financing
Resolution on 18 September 2026: 21st Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a Third-Party Allotment; total issue price: ¥2,415,000; funds to be raised: ¥1,952,915,000
Details of issuance or disposal
ItemDetails
Type of issuance or disposalCompletion of Payment of the Issue Price for the 21st Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through a Third-Party Allotment
Number of shares to be issued or disposed of34,500,000 shares (345,000 stock acquisition rights, 100 shares per right)
Issue price and disposal price¥7 per stock acquisition right
Total issue value¥2,415,000
Amount of funds to be raised¥1,952,915,000 (including the value of assets contributed upon exercise of these stock acquisition rights and related amounts, net of issuance expenses)
Payment date5 October 2026
Intended allotteePhillipCapital Securities Co., Ltd.: 345,000 stock acquisition rights (34,500,000 shares)
Intended allottee's holding policyA repurchase agreement was executed requiring approval by the Company's Board of Directors if the allottee transfers these stock acquisition rights.
Exercise priceInitially ¥57. Subject to an adjustment clause. The adjusted exercise price will be 97% of the closing price on the price calculation date, rounded up to the nearest yen, with a floor of ¥29. If exercised in excess of the limit, the exercise price will be adjusted with the closing price on the resolution date as the floor.
Exercise periodFrom 6 October 2026 to 6 October 2027
Number of Stock Acquisition RightsTotal issued: 345,000 stock acquisition rights; unexercised balance: Not disclosed
Most recent equity financingResolution on 18 September 2026: 21st Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) issued through a Third-Party Allotment; total issue price: ¥2,415,000; funds to be raised: ¥1,952,915,000
Items this document does not state (16)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Payment of the issue price for the stock acquisition rights covered by the Board of Directors' resolution dated 18 September 2026 has been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Issue Price of the 21st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment | BrightPath Biotherapeutics Co.,Ltd. (4594) timely disclosure | Komori